699 related articles for article (PubMed ID: 25756942)
1. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
McMurray JJ
Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
[TBL] [Abstract][Full Text] [Related]
2. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
[TBL] [Abstract][Full Text] [Related]
3. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
4. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
5. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
6. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
Jhund PS; McMurray JJ
Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
[TBL] [Abstract][Full Text] [Related]
7. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
Macdonald PS
Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
[TBL] [Abstract][Full Text] [Related]
9. Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF): paragon of a study or further investigation paramount?
Krum H
Circulation; 2015 Jan; 131(1):11-2. PubMed ID: 25411157
[No Abstract] [Full Text] [Related]
10. Angiotensin-Neprilysin Inhibition as a Paradigm for All?
Vaduganathan M; Desai AS
Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488
[TBL] [Abstract][Full Text] [Related]
11. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
Cannon JA; Shen L; Jhund PS; Kristensen SL; Køber L; Chen F; Gong J; Lefkowitz MP; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
Eur J Heart Fail; 2017 Jan; 19(1):129-137. PubMed ID: 27868321
[TBL] [Abstract][Full Text] [Related]
12. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
Balmforth C; Simpson J; Shen L; Jhund PS; Lefkowitz M; Rizkala AR; Rouleau JL; Shi V; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
JACC Heart Fail; 2019 Jun; 7(6):457-465. PubMed ID: 31078482
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Packer M; McMurray JJ; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile M; Andersen K; Arango JL; Arnold JM; Bělohlávek J; Böhm M; Boytsov S; Burgess LJ; Cabrera W; Calvo C; Chen CH; Dukat A; Duarte YC; Erglis A; Fu M; Gomez E; Gonzàlez-Medina A; Hagège AA; Huang J; Katova T; Kiatchoosakun S; Kim KS; Kozan Ö; Llamas EB; Martinez F; Merkely B; Mendoza I; Mosterd A; Negrusz-Kawecka M; Peuhkurinen K; Ramires FJ; Refsgaard J; Rosenthal A; Senni M; Sibulo AS; Silva-Cardoso J; Squire IB; Starling RC; Teerlink JR; Vanhaecke J; Vinereanu D; Wong RC;
Circulation; 2015 Jan; 131(1):54-61. PubMed ID: 25403646
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril/Valsartan (LCZ696) in Heart Failure.
Khder Y; Shi V; McMurray JJV; Lefkowitz MP
Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
Książczyk M; Lelonek M
Heart Fail Rev; 2020 May; 25(3):393-402. PubMed ID: 31713710
[TBL] [Abstract][Full Text] [Related]
17. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
Desai AS; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Chen F; Gong J; Rizkala AR; Brahimi A; Claggett B; Finn PV; Hartley LH; Liu J; Lefkowitz M; Shi V; Zile MR; Solomon SD
Eur Heart J; 2015 Aug; 36(30):1990-7. PubMed ID: 26022006
[TBL] [Abstract][Full Text] [Related]
18. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz M; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2014 Jul; 16(7):817-25. PubMed ID: 24828035
[TBL] [Abstract][Full Text] [Related]
19. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
Desai AS; Solomon S; Claggett B; McMurray JJ; Rouleau J; Swedberg K; Zile M; Lefkowitz M; Shi V; Packer M
Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296397
[TBL] [Abstract][Full Text] [Related]
20. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.
Simpson J; Jhund PS; Silva Cardoso J; Martinez F; Mosterd A; Ramires F; Rizkala AR; Senni M; Squire I; Gong J; Lefkowitz MP; Shi VC; Desai AS; Rouleau JL; Swedberg K; Zile MR; McMurray JJV; Packer M; Solomon SD;
J Am Coll Cardiol; 2015 Nov; 66(19):2059-2071. PubMed ID: 26541915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]